

Laura Ferrer-Font

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3895095/publications.pdf>

Version: 2024-02-01

10
papers

292
citations

1040056

9
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

436
citing authors

#	ARTICLE	IF	CITATIONS
1	OMIP 083: A 21â€marker 18â€color flow cytometry panel for inâ€depth phenotyping of human peripheral monocytes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 374-379.	1.5	12
2	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. <i>Oncolmmunology</i> , 2022, 11, .	4.6	7
3	Panel Optimization for Highâ€Dimensional Immunophenotyping Assays Using Fullâ€Spectrum Flow Cytometry. <i>Current Protocols</i> , 2021, 1, e222.	2.9	35
4	Panel Design and Optimization for Highâ€Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry. <i>Current Protocols in Cytometry</i> , 2020, 92, e70.	3.7	84
5	Highâ€Dimensional Data Analysis Algorithms Yield Comparable Results for Mass Cytometry and Spectral Flow Cytometry Data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 824-831.	1.5	27
6	High-dimensional analysis of intestinal immune cells during helminth infection. <i>ELife</i> , 2020, 9, .	6.0	25
7	Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. <i>NMR in Biomedicine</i> , 2017, 30, e3748.	2.8	23
8	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. <i>Metabolites</i> , 2017, 7, 20.	2.9	19
9	Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. <i>Pharmaceutics</i> , 2017, 10, 24.	3.8	30
10	PPARÎ²/Î³ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1049-1058.	3.8	21